Toxicity of oral iron chelator L1

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

“…30,31 Hemoglobin levels were not measured in this study, but high-dose deferiprone therapy has previously been associated with marrow suppression in rat models. [32][33][34] A direct hyperplastic effect of deferiprone cannot be excluded; however, it has not previously been described in animal or human studies.…”

“…Nonspecific organ atrophy was observed in rats given comparable doses over 1 to 3 months. 33,34 The animals did not exhibit any physical signs of liver dysfunction and liver enzymes were not performed, so the clinical significance of the hepatomegally is undetermined.…”

Immune function in patients with β thalassaemia receiving the orally active iron‐chelating agent deferiprone

“…Partly because of the expedited administration of this agent in humans, concerns regarding potential toxicities have persisted, and evaluations in humans have been directed to abnormalities reported in animals (Olivieri & Brittenham, 1997). Concerns regarding immunologic function were raised in studies describing thymic atrophy in deferiprone-treated rats (Berdoukas et al, 1993), in a report describing fatal 'systemic lupus erythematosus' in a deferiprone-treated patient (Mehta et al, 1991a, b) and in studies reporting deferiprone-induced in vitro inhibition of human lymphocyte proliferation (Pattanapanyasat et al, 1992). Although deaths related to infection in deferiprone-treated Indian patients have been attributed to immune dysfunction (Mehta et al, 1993), pyogenic meningitis and other infections are a relatively common cause of death in thalassaemia major in India (Agarwal et al, 1993).…”

“…Concerns regarding deferiproneinduced immunologic dysfunction have been raised in animal and human studies (Agarwal et al, 1993;Berdoukas et al, 1993;Mehta et al, 1991a, b;Mehta et al, 1993) against a background of immunologic abnormalities previously reported in thalassaemia and postulated to be secondary to iron overload, chronic immuno-stimulation due to transfusions, splenectomy, or desferrioxamine therapy itself (Dwyer et al, 1987;Grady et al, 1988). We examined immune function in 36 patients with thalassaemia treated with deferiprone and 21 patients receiving long-term desferrioxamine.…”

The synthesis, molecular structure and spectra properties of sulphur and selenium deferiprone analogues

“…5 However, deferiprone, despite some advantages, also has some side effects. 6 Deferiprone is a good chelating agent not only for iron ions, but also ions of many other metals. It has been proved that Ga .…”